^
    Apply
    Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment (NCT06850506)
    Phase N/A
    Peking University People's Hospital
    Active, not recruiting
    Last update posted :
    02/27/2025
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    CDH6
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)
    Phase 1/2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/09/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EWSR1 • FLI1
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944)
    Phase 1/2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/28/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    AFP
    |
    CBL137 IV
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/31/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/23/2017
    Primary completion :
    09/30/2024
    Completion :
    10/08/2025
    NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma (TARGET-RT) (NCT06796543)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Not yet recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/01/2028
    Completion :
    03/01/2030
    EFS
    Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING) (NCT05830084)
    Phase 1
    Gustave Roussy, Cancer Campus, Grand Paris
    Recruiting
    Last update posted :
    11/28/2024
    Initiation :
    06/16/2023
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    EWSR1
    |
    Stivarga (regorafenib)
    Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors (NCT06500819)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    10/31/2024
    Initiation :
    07/11/2024
    Primary completion :
    07/01/2029
    Completion :
    07/01/2029
    CD276
    |
    cyclophosphamide
    Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma (NCT04616560)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/06/2024
    Initiation :
    03/08/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    HER-2
    |
    HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/28/2017
    Primary completion :
    09/30/2023
    Completion :
    10/01/2024
    PTEN • TSC2 • TSC1
    |
    PTEN expression • TSC1 mutation • TSC2 mutation
    |
    samotolisib (LY3023414)
    Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/13/2018
    Primary completion :
    03/31/2023
    Completion :
    09/22/2024
    RB1
    |
    Ibrance (palbociclib)
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCI-2018-00918) (NCT03449108)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/27/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • CD8 • CD28 • CD27
    |
    CD8 expression • CD28 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/08/2017
    Primary completion :
    06/30/2022
    Completion :
    09/22/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib)
    Soluble B7-H3 as a Biomarker for Osteosarcoma (NCT05942456)
    Phase N/A
    Peking University People's Hospital
    Recruiting
    Last update posted :
    05/14/2024
    Initiation :
    06/05/2023
    Primary completion :
    07/01/2024
    Completion :
    12/31/2024
    CD276
    |
    CD276 expression
    Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (NCT05703854)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/25/2024
    Initiation :
    03/29/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    PD-L1
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    SPEARHEAD-3 Pediatric Study (NCT05642455)
    Phase 1/2
    Adaptimmune
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    09/01/2023
    Primary completion :
    10/01/2026
    Completion :
    07/30/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2040
    CD276
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (NCT03721068)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    02/19/2019
    Primary completion :
    06/19/2024
    Completion :
    06/19/2039
    IL15
    |
    cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells
    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (PEPN2011) (NCT04851119)
    Phase 1/2
    Children's Oncology Group
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    11/08/2021
    Primary completion :
    06/30/2028
    Completion :
    06/30/2028
    RNF43 • CTNNB1 • TCF7L2
    |
    APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P
    |
    tegavivint (BC2059)
    Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) (NCT04668300)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    11/26/2020
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    PD-L1 • CD8 • PD-1 • CD73 • CD4
    |
    PD-L1 expression • CD73 expression
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-01) (NCT03618381)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/18/2019
    Primary completion :
    06/01/2025
    Completion :
    06/01/2040
    EGFR
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Molecular-Guided Therapy for Childhood Cancer (NCT02162732)
    Phase N/A
    Giselle Sholler
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    07/08/2014
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    MYCN
    |
    MYCN amplification
    Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone (NCT06331104)
    Phase N/A
    Changye Zou
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    06/14/2012
    Primary completion :
    08/31/2023
    Completion :
    08/31/2023
    ER
    |
    ER expression • CDKN1B expression
    Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (Micros) (NCT03737435)
    Phase N/A
    Istituto Ortopedico Rizzoli
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    12/12/2018
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    PD-L1 • CD68
    |
    Mepact (mifamurtide)
    Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (NCT02100891)
    Phase 2
    Monica Thakar
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    03/20/2013
    Primary completion :
    06/08/2020
    Completion :
    07/15/2020
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    9-ING-41 in Patients With Advanced Cancers (Actuate 1801) (NCT03678883)
    Phase 2
    Actuate Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    01/04/2019
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    BCL2
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41) • doxorubicin liposomal
    Vaccine Therapy in Treating Patients With Metastatic Cancer (NCT00020267)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/04/2024
    Initiation :
    07/01/2000
    IL2
    Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (NCT04282044)
    Phase 1
    BioEclipse Therapeutics
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    01/08/2021
    Primary completion :
    08/01/2025
    Completion :
    10/01/2026
    HER-2 • ER • PGR
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • CRX100
    Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (NCT03496402)
    Phase N/A
    Institut Curie
    Recruiting
    Last update posted :
    02/05/2024
    Initiation :
    04/20/2018
    Primary completion :
    04/19/2027
    Completion :
    08/19/2027
    MYCN
    |
    MYCN amplification
    Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (NCT01661400)
    Phase 1
    Washington University School of Medicine
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    10/26/2012
    Primary completion :
    12/27/2023
    Completion :
    12/27/2023
    CD34
    |
    cyclophosphamide • thalidomide • cyclophosphamide intravenous
    HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    12/07/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2040
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) (NCT03242382)
    Phase 2
    Grupo Espanol de Investigacion en Sarcomas
    Recruiting
    Last update posted :
    01/23/2024
    Initiation :
    03/31/2017
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    CDKN2A • CDK4
    |
    CDKN2A mutation • CDK4 overexpression
    |
    Ibrance (palbociclib)
    A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors (NCT06171282)
    Phase 1
    Shanghai Yunying Medical Technology
    Recruiting
    Last update posted :
    12/14/2023
    Initiation :
    07/12/2023
    Primary completion :
    07/12/2025
    Completion :
    07/12/2026
    IFNG • IL6 • TNFA • IL2 • IL10
    |
    R130
    In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (NCT04616248)
    Phase 1
    University of Southern California
    Recruiting
    Last update posted :
    12/06/2023
    Initiation :
    01/09/2023
    Primary completion :
    01/09/2025
    Completion :
    01/09/2026
    HER-2
    |
    PD-L1 expression
    |
    CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)
    Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy (NCT00716976)
    Phase 3
    Children's Oncology Group
    Completed
    Last update posted :
    11/09/2023
    Initiation :
    06/23/2008
    Primary completion :
    04/09/2015
    Completion :
    06/30/2021
    COMT
    |
    TPMT mutation
    |
    cisplatin
    PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (NCT06074692)
    Phase 2
    Ruijin Hospital
    Recruiting
    Last update posted :
    10/31/2023
    Initiation :
    06/01/2023
    Primary completion :
    08/30/2026
    Completion :
    12/30/2026
    BRCA
    |
    AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)
    Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    03/30/2015
    Primary completion :
    09/30/2021
    Completion :
    03/31/2023
    PD-L1 • BRAF
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (NCT02500797)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    08/13/2015
    Primary completion :
    04/01/2019
    Completion :
    04/01/2023
    PD-L1 • CTLA4
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar)
    Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors (NCT03320330)
    Phase 1/2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/31/2018
    Primary completion :
    12/31/2020
    Completion :
    09/22/2024
    SEMA4D
    |
    pepinemab (VX15)
    Observational Study on Skeletal Ewing's Sarcoma (EWOss) (NCT04845893)
    Phase N/A
    Italian Sarcoma Group
    Recruiting
    Last update posted :
    09/13/2023
    Initiation :
    06/01/2021
    Primary completion :
    05/25/2028
    Completion :
    05/25/2028
    BCOR • EWSR1